Cingulate (CING) Earnings Date & Reports

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CING is expected to report earnings to rise 6.67% to -47 cents per share on November 18

Q3'26

Est.

$-0.48

Q2'26

Beat

by $0.18

Q1'26

Missed

by $0.47

Q4'25

Est.

$-0.93

Q3'25

Missed

by $0.40

The last earnings report on August 13 showed earnings per share of -44 cents, beating the estimate of -63 cents. With 22.77K shares outstanding, the current market capitalization sits at 70.09M.

View a ticker or compare two or three

CING

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for CING